Trump Action Archive

Supporting reports

• Rep. Garcia highlights Trump-Epstein reading room at Democratic event — Rep. Robert Garcia (D-CA) mentioned at the Democratic counter-event that Jeffrey Epstein survivors had opened a "Trump Epstein reading room" in Dallas and visited it. Garcia stated that survivors were "disgusted" that Trump's lawyer Todd Blanche was giving speeches while refusing to release criminal conviction records and remaining files related to Epstein.

Supporting reports

• FDA announces temporary guidance for compounding starter parenteral nutrition products for neonates — The Food and Drug Administration published guidance establishing temporary enforcement policies for compounding certain starter parenteral nutrition drug products for neonates. The guidance applies to both pharmacy compounders under Section 503A and outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA implemented the guidance immediately without prior public comment to ensure continued patient access to essential neonatal nutrition products following the expected market exit of a predominant supplier. The guidance remains subject to subsequent public comment.
• FDA determines regulatory review period for ANDEMBRY patent term extension — The Food and Drug Administration determined the regulatory review period for ANDEMBRY (garadacimab-gxii), a human biological product for hereditary angioedema prophylaxis, as 2,528 days (1,916 testing phase, 612 approval phase). The determination, made pursuant to patent term restoration law, establishes the maximum potential patent extension length. The testing phase began July 14, 2018; the complete application was submitted October 13, 2023; approval occurred June 16, 2025. Interested parties may petition FDA by March 8, 2027, to challenge the dates or contest due diligence.
• FDA determines regulatory review period for ANKTIVA patent extension — The Food and Drug Administration has determined that the regulatory review period for ANKTIVA (nogapendekin alfa inbakicept-pmln), a human biological product approved for treating BCG-unresponsive nonmuscle invasive bladder cancer, is 3,922 days (3,222 testing phase, 700 approval phase). The determination spans from July 26, 2013 (investigational exemption effective date) through April 22, 2024 (approval date). This establishes the maximum potential patent extension length; the applicant seeks between 795 and 1,827 days of actual extension across five patents. Comments on date accuracy are due by November 9, 2026; petitions regarding applicant diligence are due by March 8, 2027.
• FDA determines regulatory review period for ANZUPGO patent extension at 3,532 days — The Food and Drug Administration determined the regulatory review period for ANZUPGO (delgocitinib), a topical treatment for chronic hand eczema, to be 3,532 days (3,167 testing phase, 365 approval phase), spanning from November 20, 2015 (investigational exemption effective date) through July 23, 2025 (NDA approval). The determination establishes the maximum potential patent extension length; the applicant seeks 1,827 days of actual extension. Comments on date accuracy are due by November 9, 2026; petitions regarding due diligence may be filed by March 8, 2027.
• GSA submits Accessibility Conformance Report Repository information collection to OMB for review — The General Services Administration's Office of Governmentwide Policy submitted a new information collection requirement to the Office of Management and Budget for review and approval regarding a centralized Accessibility Conformance Report (ACR) Repository. The repository will allow federal agencies and the public to access vendor-submitted accessibility reports for information and communication technology products, supporting Section 508 compliance and federal procurement decisions. A 60-day public comment period closed with eight comments received; GSA responded to concerns about administrative burden, public access, sustainability, and standardization.
• EPA submits non-substantive changes to three information collection requests for grant performance reporting to OMB for review — The Environmental Protection Agency published a notice soliciting public comment on proposed non-substantive revisions to three information collection requests (ICRs) governing performance reporting by EPA grant recipients. The changes align ICR forms with Executive Orders issued by the current Administration regarding naming conventions, merit-based opportunity, and state/local preparedness. The ICRs cover General Performance Reporting for Assistance Programs (ICR 2802.01), Promoting Readiness and Enhancing Proficiency to Advance Reporting and Data (ICR 2804.01), and the National Estuary Program (ICR 1500.11). EPA stated the changes are non-substantive and impose no additional burden on respondents. A 30-day public comment period ends October 9, 2026.
• FDA announces Vaccines and Related Biological Products Advisory Committee meeting on 2027 Southern Hemisphere influenza vaccine strain selection — The Food and Drug Administration published notice of a public advisory committee meeting scheduled for October 1, 2026, to discuss and recommend influenza virus vaccine strains for the 2027 Southern Hemisphere influenza season. The meeting will be held online via teleconference. FDA established a public docket (FDA-2026-N-10232) accepting comments through September 29, 2026. Background materials will be posted two business days before the meeting. Interested persons may submit written comments or request time for oral presentations by September 22, 2026.
• FDA Proposes Reinstatement of Information Collection for Human Cells, Tissues, and Cellular and Tissue-Based Products — The Food and Drug Administration published a notice soliciting public comment on the proposed reinstatement of an existing information collection under the Paperwork Reduction Act. The collection supports regulatory requirements governing human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated solely under section 361 of the Public Health Service Act. The notice invites comments on necessity, burden accuracy, quality enhancement, and burden minimization. The comment period closes November 9, 2026.
• FDA solicits public comment on proposed information collection for Pregnancy Exposure Registry Enrollment Project survey — The Food and Drug Administration announced a proposed collection of information under the Paperwork Reduction Act, seeking public comment on a voluntary survey of healthcare providers regarding barriers to patient enrollment in pregnancy exposure registries. The FDA will survey approximately 400 healthcare providers (obstetrician/gynecologists, family medicine physicians, nurse-midwives, physician assistants, specialists, and pharmacists) via internet-administered questionnaire to understand their knowledge, attitudes, and perceived obstacles to recruiting pregnant patients into drug safety registries. Results will inform regulatory guidance on registry protocol design and pregnancy labeling. The comment period closes November 9, 2026.
• EPA solicits public comment on renewal information collection for PBT chemical regulations under TSCA Section 6(h) — The Environmental Protection Agency announced a proposed renewal of an Information Collection Request (ICR No. 2599.04, OMB Control No. 2070-0213) governing reporting and compliance activities for five persistent, bioaccumulative, and toxic chemicals: decabromodiphenyl ether, phenol isopropylated phosphate, 2,4,6-tris(tert-butyl)phenol, pentachlorothiophenol, and hexachlorobutadiene. The renewal consolidates this ICR with a separate 2024 final-rule ICR, increasing total estimated annual burden to 42,309 hours across approximately 26,829 respondents. Public comment period closes November 9, 2026.
• EPA solicits public comment on renewal of information collection request for TSCA user fees — The Environmental Protection Agency announced a proposed renewal of an existing Information Collection Request (ICR No. 2569.07, OMB Control No. 2070-0208) governing user fees for administering the Toxic Substances Control Act. The ICR addresses fee collection from manufacturers and importers of chemical substances under TSCA sections 4, 5, and 6. The renewal reflects a decrease of 269 hours in estimated respondent burden compared to the prior approval. EPA solicits public comment through November 9, 2026, before submitting the final ICR to OMB for review and approval.
• FCC Invites Public Comment on Information Collection for Cable Service Rate Certification Petitions — The Federal Communications Commission published a notice requesting public comments on an information collection under the Paperwork Reduction Act. The collection concerns 47 CFR 76.916, which governs petitions filed by franchising authorities seeking recertification to regulate basic cable service rates after prior certification denial or revocation. The FCC estimates 2 respondents submitting 3 responses annually, with 10 hours per response and 30 total annual burden hours. Comments are due by November 9, 2026.
• FCC Requests Public Comments on Information Collection for Universal Service Auction Eligibility and Bidding Communications — The Federal Communications Commission issued a notice requesting public comments on an information collection under the Paperwork Reduction Act. The collection (OMB Control Number 3060-1166) pertains to FCC rules sections 1.21001 and 1.21002, which govern eligibility determinations and prohibited communications during competitive bidding for Universal Service Fund support. The FCC seeks feedback on necessity, burden estimates, and ways to minimize compliance costs for respondents, particularly small businesses. Comments are due by November 9, 2026.
• FCC requests public comments on information collection requirements for satellite and earth station licensing — The Federal Communications Commission issued a notice requesting public comments on revised information collection requirements under OMB Control No. 3060-0678, governing licensing and spectrum usage by commercial earth stations and space stations under Part 25 of FCC rules. The revision reflects two recent FCC orders: a Second Report and Order (FCC 25-48, August 8, 2025) streamlining satellite and earth station application processing, and a Report and Order (FCC 26-26, May 1, 2026) modernizing spectrum-sharing criteria for satellite broadband. The collection affects approximately 4,171 respondents with an estimated annual burden of 37,129 hours and annual cost of $7,159,040. Comments are due by November 9, 2026.
• FDA announces priority review voucher fee rate for fiscal year 2027 — The Food and Drug Administration published a notice establishing the fiscal year 2027 fee rate for using priority review vouchers at $1,798,596. This fee applies to applications for tropical disease, rare pediatric disease, or material threat medical countermeasure products submitted with a priority review voucher, in addition to standard Prescription Drug User Fee Act fees. The rate is effective October 1, 2026, through September 30, 2027, and was calculated based on the difference between average costs of priority and standard drug application reviews in fiscal year 2025, adjusted for cost increases.
• GSA releases FY 2027 CONUS per diem reimbursement rates for federal employee travel — The General Services Administration published Federal Travel Regulation Bulletin FTR 27-01, establishing maximum per diem reimbursement rates for federal employees traveling within the Continental United States during fiscal year 2027. The standard lodging rate increases by $3 to $113 per night, following a rate freeze in FY 2026. Meals and incidental expenses (M&IE) reimbursement rates remain at $68–$92, with the standard M&IE rate at $68. The rates apply to travel performed October 1, 2026, through September 30, 2027. Agencies may request GSA review of rates for specific locations if insufficient to meet necessary expenses.
• EPA solicits public comment on NASA's emergency exemption application for ortho-phthalaldehyde use on International Space Station — The Environmental Protection Agency announced receipt of a specific exemption request from NASA under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) section 18 to use ortho-phthalaldehyde (OPA) as a biocide in the International Space Station's internal active thermal control system coolant. OPA, an unregistered pesticide, would control aerobic and microaerophilic bacteria in the aqueous coolant at concentrations up to 350 mg/liter. NASA asserts OPA is the most effective biocide meeting safety and material-compatibility criteria, with no adequate alternative long-term solution available. The EPA is soliciting 15 days of public comment before deciding whether to grant the exemption, which NASA expects to continue through 2030.
• EPA solicits public comment on renewal of information collection for soil and non-soil fumigant risk mitigation measures — The Environmental Protection Agency announced a proposed renewal of an existing Information Collection Request (ICR No. 2451.04, OMB Control No. 2070-0197) governing fumigant risk mitigation activities. The ICR documents paperwork requirements for fumigant users, registrants, and states implementing risk mitigation measures under the Federal Insecticide, Fungicide, and Rodenticide Act. The renewal reflects an increase of 333,720 burden hours and adds Ethylene Oxide-using facilities to the scope. Public comment period closes November 10, 2026.
• FDA finalizes removal of PABA and trolamine salicylate from OTC sunscreen monograph — The Food and Drug Administration issued final administrative order OTC000008-1, removing aminobenzoic acid (PABA) and trolamine salicylate as permitted active ingredients in over-the-counter sunscreen drug products under OTC Monograph M020. FDA determined these ingredients are not generally recognized as safe and effective (GRASE) because available safety data shows risks outweigh benefits. The final order was announced on the FDA website and published in the Federal Register on September 11, 2026, following a proposed order issued in September 2021 with an extended comment period.
• FDA solicits public comment on medical device tracking information collection requirements — The Food and Drug Administration published a notice requesting public comment on the proposed extension of an existing information collection under the Paperwork Reduction Act. The collection pertains to tracking requirements for class II and III medical devices that meet specified criteria—including those likely to cause serious adverse health consequences, implanted devices, or life-sustaining devices used outside facilities. The comment period closes November 10, 2026. FDA estimates 22,000 potential respondents and a total annual burden of approximately 663,000 hours across reporting, recordkeeping, and third-party disclosure activities.
• GSA rescinds and removes FMR Bulletin B-51 on executive agency property reporting — The General Services Administration rescinded and removed Federal Management Regulation (FMR) Bulletin B-51, which required annual executive agency reports on exchange/sale and personal property furnished to non-federal recipients. GSA cited the bulletin as outdated; the reporting requirement was eliminated by FMR Case 2025-05, which aligned FMR with the administration's deregulatory priorities following Executive Order 14192 (Unleashing Prosperity Through Deregulation, January 31, 2025). The action became effective immediately on September 11, 2026.
• GSA submits OMB review request for annual SAM.gov certification of higher education compliance with Executive Order 14400 on college sports — The General Services Administration submitted to the Office of Management and Budget a request to approve a new information collection requiring registered higher education institutions with $20 million or more in intercollegiate athletics revenue to certify annually their compliance with Executive Order 14400 (Urgent National Action to Save College Sports) via the System for Award Management (SAM.gov). The collection affects approximately 11,720 respondents with an estimated annual burden of 14,620 responses and 181,584.50 hours. A 30-day public comment period closes October 13, 2026.